NDAORALFOR SUSPENSION
Approved
Dec 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
VIBRAMYCIN (doxycycline) by Pfizer is 12. First approved in 1967.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIBRAMYCIN (doxycycline) is a tetracycline-class antibiotic available as an oral suspension that has been approved since 1967 for treating bacterial infections and inflammatory conditions including rosacea. The exact mechanism in rosacea treatment remains unknown, but doxycycline works via protein synthesis inhibition in bacterial cells. It is administered orally with strict food interaction protocols to maximize bioavailability.
$0.005BPart D
LOE ApproachingStable
Product approaching loss of exclusivity with minimal Part D claims suggests a mature, stable generic-facing asset with small commercial team and limited growth runway.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of doxycycline in the treatment of inflammatory lesions of rosacea is unknown. 12.3 Pharmacokinetics Doxycycline capsules are not bioequivalent to other doxycycline products. The pharmacokinetics of doxycycline following oral administration of…
Worked on VIBRAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.